top of page

January 05, 2024

roundbreaking advancements in medical research are being made as K2 Medical Research, Magruder Eye Institute, and RetiSpec join forces to redefine Alzheimer’s research through AI-driven technology...

January 05, 2024

K2 Medical Research has partnered with Magruder Eye Institute and RetiSpec in a research pilot to improve access to clinical trials, using AI-driven technology to prescreen eligible candidates in an eye care setting...

December 24, 2023

A technology that can spot signs of Alzheimer’s disease earlier than ever before...

December 20, 2023

The eye could be the window to Alzheimer’s thanks to new artificial intelligence tools that promise to make scanning for the illness as easy as checking your eyesight...

December 20, 2023

In response to Ontario’s rising prevalence of dementia, RetiSpec – an OBI portfolio company – and the Toronto Memory Program, in collaboration with the Alzheimer’s Society of Toronto, designed and tested a new care pathway for identifying people with Alzheimer's disease...

December 08, 2023

RetiSpec is designed to look at the distinctive signs of AD, as well as Parkinson's disease (PD), vascular dementia, and amyotrophic lateral sclerosis...

November 09, 2023

RetiSpec’s technology works by looking for changes in the retina that suggest early AD. Currently, RetiSpec is conducting clinical trials at multiple optometry clinics and is hoping the cameras will be approved for everyday use in optometry clinics in early 2025...

November 06, 2023

RetiSpec is currently conducting clinical trials at multiple optometry clinics in Canada and the United States. At Victoria Village Optometry in Toronto, one of the clinical trial sites, optometrist Dr. Negar Sohbati asks patients over age 55 if they have memory concerns and, if so, offers them an opportunity to participate in the study...

October 11, 2023

To make the diagnosis process faster and cheaper, some technology companies are now turning to AI tools to analyze patient data for signs of Alzheimer's...

October 10, 2023

RetiSpec has developed an artificial-intelligence algorithm that it says can analyze results from an eye scanner and detect signs of Alzheimer’s 20 years before symptoms develop...                                                                                      

October 10, 2023

RetiSpec, a Toronto-based startup, has developed an artificial intelligence (AI) algorithm that can analyze eye scanner results and detect signs of Alzheimer’s up to 20 years before symptoms appear...

September 15, 2023

A new breakthrough approach being developed right here in Canada is using retinal scans and artificial intelligence to deliver a diagnosis, the company based in Toronto called RetiSpec it's at the forefront of this research...

August 29, 2023

Founder of RetiSpec hopes the technology will make screening more widespread: “Eye clinics are like Starbucks — they’re everywhere.”

July 24, 2023

RetiSpec launched a pilot project with the Toronto Memory Program, the Alzheimer Society of Canada and other brain health organizations that puts their tech in Toronto community eye clinics...

July 20, 2023

RetiSpec, a Toronto-based medical imaging company, is utilizing artificial intelligence (AI) and retinal scans to detect early signs of Alzheimer’s...

July 19, 2023

The relentless pursuit of detecting and combating the effects of Alzheimer’s disease has posed a grueling battle for families and the medical community, but a simple eye scan at an optometrist’s office may one day help ease that burden...

May  24, 2023

RetiSpec: A promising approach to dementia screening through optometry...

May  19, 2023

RetiSpec, a Toronto-based medical AI company, captures images of the retina and uses AI to look for abnormal concentrations of a protein linked to the disease...

April  13, 2023

The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, invested more than $4.55 million in funding to support early-stage innovations aimed at improving the quality of life for older adults, people living with dementia, and their caregivers...

December 2, 2022

Now researchers are testing a new device that may make testing easier and may lead to a diagnosis earlier....

November 3, 2022

This unique initiative to screen for Alzheimer's disease in community settings involves a strong partnership between optometry clinics and the Alzheimer Society of Toronto...

September 19, 2022

An estimated 6.5 million Americans are currently living with Alzheimer’s. Currently, there is no cure, few effective treatments, and the only way to diagnose it is with an expensive PET scan or a painful lumbar puncture which measures spinal fluid...

September 01, 2022

Early detection and accurate diagnosis are key to getting people on the right care and treatment path—and tools such as retinal imaging can aid both patients and physicians in that journey, says Rebecca Edelmayer...

July 30, 2022

A company called RetiSpec, backed in part by the foundation, is developing a retinal test that detects neurodegenerative changes. “The eye is the window to the brain,” explains Fillit...

July 26, 2022

The Alzheimer's Drug Discovery Foundation (ADDF) announces the second phase of its Diagnostics Accelerator with new philanthropic partners and an additional $50 million in financial commitments, bringing the total capital to $100 million earmarked to speed development of new and innovative tests for early diagnosis of Alzheimer's disease and related dementias.

July 20, 2022

As a graduate student, Cindi Morshead figured out where stem cells could be hiding in the brain. Now, as scientists mark World Brain Day, she explains how gene therapies could soon regrow neurons lost to stroke and give patients reason to hope...

July 05, 2022

As more therapies potentially enter the market to treat Alzheimer’s disease, it will be imperative to use new technology to confirm diagnosis, Cohen said. “You wouldn’t give someone chemotherapy unless you confirmed they had cancer,” she said. “Times are changing with Alzheimer’s disease, matching the technology of diagnostics with what’s going on with therapeutics is an ideal pairing.”...

June 03, 2022

RetiSpec and Toronto Memory Program are One of Twelve Select Recipients of the Inaugural Global Davos Alzheimer's Collaborative Grant Program for Healthcare System Preparedness...

June 02, 2022

Progressive Medical Research is using a revolutionary retinal scanning process by RetiSpec. The scanning process has the ability to detect the early stages of Alzheimer’s...

June 02, 2022

An innovative new project in Toronto will combine optometry and community-based cognitive testing to improve Alzheimer’s screening and enable the early detection of the progressive neurodegenerative disorder. The project — launching in Ontario, Canada — will be led by the medical imaging company RetiSpec and the community-based medical center Toronto Memory Program...

May 25, 2022

This project will provide a robust and informative model that can be scaled across Canada as well as to global jurisdictions and is uniquely positioned to strengthen and better prepare our healthcare systems...

May 25, 2022

"RetiSpec's technology can be used to rapidly and noninvasively screen people during their routine eye exams, offering an easy, accessible, and scalable alternative to current methods of Alzheimer's disease detection," Eliav Shaked, CEO, and Co-founder of RetiSpec said...

May 23, 2022

The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease, today announced the recipients of a grant program aiming for early detection of cognitive symptoms...

March 30, 2022

RetiSpec and retinal imaging in general, could have an extremely positive impact on the AD community, Sharon Cohen, MD, FRCPC, believes. Cohen, a neurologist and assistant professor at the University of Toronto, led the validation study of RetiSpec... 

March 25, 2022

Developments in non-invasive retinal imaging technologies, such as RetiSpec, have provided a means to study neuronal and vascular structures in the retina in people with AD. In a validation study, RetiSpec’s hyperspectral retinal imaging was effective... 

March 21, 2022

Sharon Cohen, MD, FRCPC, lead investigator of a validation study that looked at RetiSpec, believes these types of approaches hold immense potential in the drug development field. Despite the increasing amount of funds poured into the therapeutic... 

March 18, 2022

 RetiSpec’s hyperspectral retinal imaging system is adding to the promise of these approaches, most recently with positive data presented at the 14th Clinical Trials in Alzheimer Disease Conference, November 9-12, 2021. In a cohort of 108 participants...

March 14, 2022

Although investigational, lead author Sharon Cohen, MD, believes there is great potential for retinal approaches such as those being taken by RetiSpec. Cohen, a neurologist and assistant professor at the University of Toronto, sat down with...

March 14, 2022

At the 14th Clinical Trials on Alzheimer’s Disease Conference (CTAD), November 9-12, 2021, investigators presented research that demonstrated RetiSpec’s ability to predict brain amyloid status. In a cross-sectional validation study, 108 patients who... 

February 11, 2022

As attention turns to new drugs that can address the growing burden of Alzheimer’s disease (AD) in an aging global population, Retispec Inc. has developed a noninvasive test that may be able to detect early signs of the neurodegenerative...

February 3, 2022

Gentex Corporation is the presenting sponsor of this year's Michigan International Auto Show and they're also leaders when it comes to automotive technology. They're starting to take their automotive expertise into new markets as well...

January 5, 2022

To mark January as Alzheimer’s Awareness Month, we’re joined by Sharon Cohen, a neurologist who runs Canada’s busiest memory clinic, in Toronto... 

December 7, 2021

A huge benefit of RetiSpec and other early-detection tools is that they are inexpensive, non-invasive and quick. Currently, Alzheimer’s is diagnosed with lumbar punctures, cognitive tests and PET scans...

November 9, 2021

We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems...

October29, 2021

The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Hargreaves...

September 21, 2021

Billionaire philanthropist speaks of the new breakthroughs in diagnostics that are being conducted through Diagnostic Accelerator, a venture that raises philanthropic capital for research in this field...

September 20, 2021

Gates Notes

New breakthroughs in Alzheimer’s diagnostics may someday soon let us substantially alter the course of the disease...

June 22, 2021

Dr. Karen Cross was doing everything in her power to prevent her diabetic grandfather from needing an amputation. But that power was limited by distance — Cross works in Toronto and her grandfather was in rural Newfoundland...

April 24, 2021

With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick...

April 20, 2021

Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who are contributing to GAP’s Bio-Hermes Study...

November 21, 2020

Toronto-based biomedical engineers Eliav Shaked and Roy Kirshon are working on a quick, non-invasive retinal diagnostic for patients decades away from showing symptoms of dementia...

October 5, 2020

RetiSpec (Toronto, Canada) is an AI medical imaging company developing tools for the early detection of disease biomarkers in the eye.

RetiSpec's technology uses a device to perform a simple eye scan, which then can be used to identify the presence of certain disease biomarkers ...

November 11, 2019

“In collaboration with our industry partner, RetiSpec, we hope to accelerate clinical development of this early detection technique and provide existing or new treatments the best chance for success,” added Vince. This study was funded by the...

October 25, 2019

RetiSpec technology is hoped to be able to match this early detection ability without the shortcomings of the other approaches. Eliav Shaked, ...

October 08, 2019

Disruptive Technology Harnesses Hyperspectral Imagery and Machine-Learning to Allow for Rapid and Cost-Effective Identification of Alzheimer's Biomarkers ...

October 08, 2019

Could a simple eye exam detect signs of Alzheimer's disease?

October 14, 2019

RetiSpec's technology is designed to identify Alzheimer's biomarkers years before the emergence of clinical symptoms.

September 23, 2019

A new intiative from the Toronto Memory Project is trying to use retina scans to determine if patient's have Alzheimer's disease

September 19, 2019

CABHI is working with RetiSpec to accelerate its technology in Ontario and Canada. Through the Industry Innovation Partnership Program (I2 P2 ), CABHI matched RetiSpec with the Toronto Memory Program, a medical facility with one of...

 October 24, 2018

The University of Minnesota and Toronto-based medical imaging company RetiSpec have announced a collaboration and licensing

October17, 2018

The collaboration provides RetiSpec, a startup based in Toronto, Canada, with exclusive access to an imaging system developed by researchers ...

June 22, 2016

University of Minnesota researchers have developed technology to detect early signs of Alzheimer's. Utilizing the non-invasive technology, researchers from the Center for Drug Design were able to visualize clear patterns of changes suggesting the...

In The Press

bottom of page